Mercy Health Partners-Hackley Campus | ClinicalTrials HQ

6 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	Head and Neck Neoplasms, Mouth Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Stomatognathic Diseases, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, lymphoid interstitial pneumonia, mouth disorder, neoplasm, salivary gland cancer, salivary gland disorder, salivary gland squamous cell carcinoma, squamous cell carcinoma, tongue cancer, tongue carcinoma, tongue disorder	Active, not recruiting	Phase 3	2026-10-01		NCT00588770
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer	breast adenocarcinoma	Active, not recruiting	Phase 3	2026-10-01		NCT00433511
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)	Neoplasms by Site, Skin and Connective Tissue Diseases, breast adenocarcinoma, breast disorder, breast neoplasm, neoplasm, skin disorder	Active, not recruiting	Phase 3	2026-10-01		NCT00310180
Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia	Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone marrow disorder, hematologic disorder, leukemia, myeloid leukemia, neoplasm	Active, not recruiting	Phase 2	2026-08-26		NCT00070499
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma	DS Stage I Multiple Myeloma; DS Stage II Multiple Myeloma; DS Stage III Multiple Myeloma	Active, not recruiting	Phase 3	2026-07-29		NCT00644228
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer	Adnexal Diseases, Brenner tumor, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, carcinoma, clear cell adenocarcinoma, connective tissue neoplasm, cystic, mucinous, and serous neoplasm, endocrine system disorder, epithelial neoplasm, fallopian tube clear cell adenocarcinoma, fallopian tube disorder, fallopian tube endometrioid adenocarcinoma, fallopian tube mucinous adenocarcinoma, fallopian tube neoplasm, fallopian tube serous adenocarcinoma, fallopian tube transitional cell carcinoma, female reproductive system disorder, female reproductive system neoplasm, fibroepithelial neoplasm, gonadal disorder, malignant endocrine neoplasm, mucinous adenocarcinoma, neoplasm, ovarian Brenner tumor, ovarian cancer, ovarian clear cell adenocarcinoma, ovarian clear cell malignant adenofibroma, ovarian disorder, ovarian endometrioid adenocarcinoma, ovarian seromucinous carcinoma, ovarian serous adenocarcinoma, ovarian transitional cell carcinoma, primary peritoneal serous adenocarcinoma, undifferentiated carcinoma, undifferentiated ovarian carcinoma	Active, not recruiting	Phase 3	2025-12-30		NCT00565851